Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference
February 27 2020 - 6:00AM
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced
today that Dr. Henry Ji, Chairman and CEO, will present at the
9th Annual LEERINK Partners Global Healthcare Conference
(Lotte New York Palace Hotel, New York) on Thursday Feb 27 at
11:00-11:25 AM (Presentation Room Adams).
Key updates:
- Both RTX Phase 1b Cancer Pain and Phase 1b Osteoarthritis (OA)
Knee Pain studies have completed initial enrollment with
preliminary positive results: no dose limiting toxicities observed
and significant efficacy signal confirmed.
- Allogeneic “Off-the-Shelf” Dimeric Antigen Receptor-T (DAR-T)
cell therapy products targeting hematologic cancer targets (BCMA,
CD38, CD20, CD123) and solid tumor targets (GD2, CEA, EGFR, and
many others) have been successfully produced.
- Proprietary DAR construct for coronavirus targeting, including
COVID-19, has been successfully generated; COVID-19 targeting DAR-T
cells and DAR-NK cells will be produced next in Sorrento’s cGMP
facilities (San Diego) as part of the IND-enabling package
necessary to promptly initiate human clinical studies.
DAR-T specific developments:
Sorrento’s proprietary DAR structure offers potential advantages
over the conventional CAR (chimeric antigen receptor) structure
by:
- increasing specificity and functionality of the DAR-T cells as
compared to CAR-T cells due to higher inherent stability of the Fab
fragment used in the DAR
- potentially reducing the clinical dose due to increased
functional activity (preclinical data)
In addition to the proprietary DAR structure, Sorrento’s
proprietary non-viral knockout-knockin (KOKI) manufacturing
approach offers several potential benefits over virus-based
transduction currently used for CAR-T therapies:
- site-specific integration of transgenes into pre-selected loci
in the T cell genome
- enhanced clonal expansion of the DAR-T cells
- streamlined method for transgene construct production without
the need for laborious and time-consuming virus production, release
and validation processes, resulting in a shorter research and
development timelines for IND-enabling activities.
Combining those approaches, the allogeneic DAR-T products could
potentially have the following major advantages over current
autologous CAR-T therapy technologies:
- off-the-shelf availability allowing for immediate patient
access to allogeneic cell therapies (by using healthy donor cells
instead of modifying a patients’ own cells)
- significantly improved cost of goods (by making much greater
patient-doses in each manufacturing run)
- easier execution of global trials and international market
access due to established shipping logistics and distribution
processes (drug like product)
Beyond targeting cancer related indications, which is the
primary focus of Sorrento’s immuno-oncology business, Sorrento
believes it can apply its KOKI DAR-T platform against pandemic
infectious pathogens, including but not limited to coronaviruses,
HBV, HIV, malaria, measles and fungi.
The potential spread of the COVID-19 coronavirus from Wuhan,
China is only one example of how quickly a local infection can
become a pandemic. Sorrento’s agile KOKI DAR-T and DAR-NK cell
therapy platforms, coupled with in-house cGMP manufacturing
facilities, should allow for emergency adoptive T cell and innate
NK cell therapies being produced rapidly for clinical testing.
COVID_DAR_001 has been added to the Sorrento development
pipeline and allocated internal priority both to demonstrate the
maturity, agility and development readiness of the proprietary
platform and to address an emergency and potentially critical
patient need in the upcoming months.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric,
biopharmaceutical company developing new therapies to turn
malignant cancers into manageable and possibly curable diseases.
Sorrento's multimodal multipronged approach to fighting cancer is
made possible by its’ extensive immuno-oncology platforms,
including key assets such as fully human antibodies (“G-MAB™
library”), clinical stage immuno-cellular therapies (“CAR-T”),
development stage DAR-T cell therapies, intracellular targeting
antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and
clinical stage oncolytic virus (“Sephrevir®”).
Sorrento's commitment to life-enhancing therapies for cancer
patients is also demonstrated by our effort to advance a
first-in-class (TRPV1 agonist) non-opioid pain management small
molecule in Resiniferatoxin (“RTX”) and ZTlido®. Resiniferatoxin is
completing a Phase 1b trial for intractable pain associated with
cancer and a Phase 1b trial in osteoarthritis (OA) patients.
ZTlido® was approved by the FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com
Forward-Looking Statements
This press release and any statements made for and during any
presentation or meeting contain forward-looking statements related
to Sorrento Therapeutics, Inc., under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995
and subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include statements regarding the expectations for
Sorrento's and its subsidiaries' technologies and product
candidates, including, but, not limited to, resiniferatoxin (RTX)
and DAR-T, the clinical potential of RTX, potential advantages of
Sorrento’s DAR-T program and NK and CAR gene editing technologies,
potential benefits of the KOKI manufacturing approach, potential
advantages of allogeneic DAR-T products over current autologous
CAR-T therapy and potential applications for the KOKI DAR-T and
DAR-NK platforms. Risks and uncertainties that could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements, include, but are not
limited to: risks related to Sorrento's and its subsidiaries'
technologies and prospects, including, but not limited to, RTX,
DAR-T, KOKI and DAR-NK; risks related to seeking regulatory
approvals and conducting and obtaining results of clinical trials,
including, but not limited to, the Phase 1b studies and any prior
RTX studies in animals; costs associated with clinical trials, the
clinical and commercial success of RTX; the viability and success
of using RTX for treatments in certain therapeutic areas, including
for the treatment of intractable pain associated with cancer,
Sorrento’s DAR-T, KOKI and DAR-NK programs and drug products; risks
related to seeking regulatory approvals and conducting clinical
trials and other risks that are described in Sorrento's most recent
periodic reports filed with the Securities and Exchange Commission,
including Sorrento's Annual Report on Form 10-K for the year ended
December 31, 2018, and subsequent Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission, including the
risk factors set forth in those filings. Investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date of this release and we undertake no
obligation to update any forward-looking statement in this press
release except as required by law.
Media and Investor Relations
Contact: Alexis Nahama, SVP Corp Development
Telephone: 1.858.203.4120
Email: mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of
Sorrento Therapeutics, Inc.
ZTlido® and G-MAB™ are trademarks owned by Scilex
Pharmaceuticals, Inc. and Sorrento, respectively.
Seprehvir®, is a registered trademark of Virttu Biologics
Limited, a wholly owned subsidiary of TNK Therapeutics, Inc. and
part of the group of companies owned by Sorrento Therapeutics,
Inc.
All other trademarks are the property of their respective
owners.
© 2020 Sorrento Therapeutics, Inc. All Rights Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2023 to Apr 2024